149 related articles for article (PubMed ID: 16575684)
1. von Willebrand factor-cleaving protease (ADAMTS13) in the course of stem cell transplantation.
Kentouche K; Zintl F; Angerhaus D; Fuchs D; Hermann J; Schneppenheim R; Budde U
Semin Thromb Hemost; 2006 Mar; 32(2):98-104. PubMed ID: 16575684
[TBL] [Abstract][Full Text] [Related]
2. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Furlan M; Robles R; Galbusera M; Remuzzi G; Kyrle PA; Brenner B; Krause M; Scharrer I; Aumann V; Mittler U; Solenthaler M; Lämmle B
N Engl J Med; 1998 Nov; 339(22):1578-84. PubMed ID: 9828245
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in thrombotic thrombocytopenic purpura.
Sadler JE; Moake JL; Miyata T; George JN
Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
[TBL] [Abstract][Full Text] [Related]
4. Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children.
Loirat C; Veyradier A; Girma JP; Ribba AS; Meyer D
Semin Thromb Hemost; 2006 Mar; 32(2):90-7. PubMed ID: 16575683
[TBL] [Abstract][Full Text] [Related]
5. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.
Furlan M; Lämmle B
Best Pract Res Clin Haematol; 2001 Jun; 14(2):437-54. PubMed ID: 11686108
[TBL] [Abstract][Full Text] [Related]
6. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.
Zheng XL
Annu Rev Med; 2015; 66():211-25. PubMed ID: 25587650
[TBL] [Abstract][Full Text] [Related]
7. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
Kato S; Fujimura Y
Rinsho Byori; 2015 Oct; 63(10):1228-36. PubMed ID: 26897861
[TBL] [Abstract][Full Text] [Related]
8. [From gene to disease; congenital thrombotic thrombocytopenic purpura due to mutations in the ADAMTS13 gene].
Schiphorst RH; van de Kar NC; van den Heuvel LP
Ned Tijdschr Geneeskd; 2003 Dec; 147(49):2422-4. PubMed ID: 14694551
[TBL] [Abstract][Full Text] [Related]
9. Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation.
Peyvandi F; Siboni SM; Lambertenghi Deliliers D; Lavoretano S; De Fazio N; Moroni B; Lambertenghi Deliliers G; Mannuccio Mannucci P
Br J Haematol; 2006 Jul; 134(2):187-95. PubMed ID: 16846477
[TBL] [Abstract][Full Text] [Related]
10. [Genetic polymorphism of von Willebrand factor (VWF)-cleaving protease, ADAMTS13].
Kokame K
Brain Nerve; 2008 Nov; 60(11):1325-32. PubMed ID: 19069166
[TBL] [Abstract][Full Text] [Related]
11. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
Tersteeg C; de Maat S; De Meyer SF; Smeets MW; Barendrecht AD; Roest M; Pasterkamp G; Fijnheer R; Vanhoorelbeke K; de Groot PG; Maas C
Circulation; 2014 Mar; 129(12):1320-31. PubMed ID: 24449821
[TBL] [Abstract][Full Text] [Related]
12. FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients.
Mancini I; Valsecchi C; Lotta LA; Deforche L; Pontiggia S; Bajetta M; Palla R; Vanhoorelbeke K; Peyvandi F
Thromb Haemost; 2014 Aug; 112(2):297-303. PubMed ID: 24740645
[TBL] [Abstract][Full Text] [Related]
13. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.
Tsai HM; Lian EC
N Engl J Med; 1998 Nov; 339(22):1585-94. PubMed ID: 9828246
[TBL] [Abstract][Full Text] [Related]
14. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura.
Furlan M
Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):243-55. PubMed ID: 15030284
[TBL] [Abstract][Full Text] [Related]
15. [ADAMTS13, von Willebrand factor specific cleaving protease].
Veyradier A; Coppo P
Med Sci (Paris); 2011 Dec; 27(12):1097-105. PubMed ID: 22192749
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond.
Lian EC
Semin Thromb Hemost; 2005 Dec; 31(6):625-32. PubMed ID: 16388413
[TBL] [Abstract][Full Text] [Related]
17. The potential therapeutic benefit of targeting ADAMTS13 activity.
Eerenberg ES; Levi M
Semin Thromb Hemost; 2014 Feb; 40(1):28-33. PubMed ID: 24338607
[TBL] [Abstract][Full Text] [Related]
18. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases.
Franchini M; Montagnana M; Targher G; Lippi G
Semin Thromb Hemost; 2007 Nov; 33(8):787-97. PubMed ID: 18175284
[TBL] [Abstract][Full Text] [Related]
19. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
[TBL] [Abstract][Full Text] [Related]
20. Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS).
Licht C; Stapenhorst L; Simon T; Budde U; Schneppenheim R; Hoppe B
Kidney Int; 2004 Sep; 66(3):955-8. PubMed ID: 15327386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
